Open-Label, Dose-Finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Patients With Suspected or Confirmed Bacterial Infections

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Gram Positive Bacterial Infections
Interventions
DRUG

Oritavancin

Trial Locations (8)

40202

Univ of Louisville, Norton Children's Research Institute, Louisville

43606

Toledo Children's Hospital, Toledo

44106

Rainbow Babies and Children's Hospital, Cleveland

68114

University of Nebraska Medical Center, Omaha

72202

Arkansas Children's Hospital, Little Rock

90502

UCLA Harbor Medical Center, Torrance

92123

Rady Children's Hospital, San Diego

92868

Childrens Hospital of Orange County, Orange

Sponsors
All Listed Sponsors
lead

Melinta Therapeutics, LLC

INDUSTRY

NCT02134301 - Open-Label, Dose-Finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Patients With Suspected or Confirmed Bacterial Infections | Biotech Hunter | Biotech Hunter